|

Impact of Obesity on Microvascular Insulin Action and Cardiorespiratory Fitness in Type 1 Diabetes

RECRUITINGN/ASponsored by University of Virginia
Actively Recruiting
PhaseN/A
SponsorUniversity of Virginia
Started2026-02-23
Est. completion2030-06-30
Eligibility
Age21 Years – 50 Years
Healthy vol.Accepted
Locations1 site

Summary

The purpose of this study is: * To see if insulin resistance (how sensitive your muscle tissue is to insulin) is associated with lower cardio fitness in people with Type 1 diabetes compared to healthy controls, before and after a High Intensity Interval Training (HIIT) exercise program. * To see if being overweight and having Type 1 diabetes is associated with lower cardio fitness compared to overweight healthy controls, before and after a HIIT exercise program.

Eligibility

Age: 21 Years – 50 YearsHealthy volunteers accepted
Inclusion Criteria:

* • Male or female ≥21 and ≤50 years old

  * For persons with T1D: Disease duration ≥ 5 years and HbA1c ≤ 8.5% on multiple daily insulin injection or insulin pump
  * Body mass index: ≥19 and ≤27 kg/m2 for control and T1D, ≥30 and ≤40 kg/m2 (27.5 to 37.5 for Asian Americans) for obesity and T1D + obesity. BMI is limited to ≤40 kg/m2 (37.5 for Asian Americans) for easier vascular access and cardiac imaging.
  * Stable use of non-insulin medications for over 6 months other than estrogen/progesterone containing medications which must be discontinued at least 3 months prior to the study (intrauterine devices may be continued due to limited systemic absorption)

Exclusion Criteria:

* • Acute or chronic disease other than T1D or obesity

  * History of microvascular or macrovascular diabetes complications
  * History of diabetic ketoacidosis in the past 24 months
  * History of hypoglycemia unawareness
  * Recently active (\>20 min of moderate/high intensity exercise, 2 times/week)
  * Subjects who are smokers or who have quit smoking \<5 years
  * Subjects with hypertriglyceridemia (\>400 mg/dl)
  * Current use of vasoactive medications (i.e. calcium channel blockers, angiotensin-converting enzyme or renin inhibitors, angiotensin-receptor blockers, nitrates, alpha- or beta-blockers, or diuretics).
  * Females taking oral contraceptives in the past 3 months
  * Subjects with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or malignancy
  * Pregnant (as evidenced by positive pregnancy test) or nursing women
  * Musculoskeletal condition preventing participation in exercise testing or exercise training
  * History of gastroparesis
  * Pulse oximetry \<90%

Conditions3

DiabetesOverweightType 1 Diabetes

Locations1 site

University of Virginia
Charlottesville, Virginia, 22908
Zhenqi Liu, MD434-924-5247zl3e@UVAhealth.org

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.